CD8A and neoplasm: Berinstein and colleagues used a 7-peptide vaccine targeting 7 different tumor antigens in a cohort of 23 adenocarcinomas that included three metastatic breast cancers and showed SD lasting 8 months in one patient and CD8+ T-cell responses in all three patients43.